Analyst Price Target is $20.14
▲ +91.11% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Acrivon Therapeutics in the last 3 months. The average price target is $20.14, with a high forecast of $26.00 and a low forecast of $14.00. The average price target represents a 91.11% upside from the last price of $10.54.
Current Consensus is
Buy
The current consensus among 7 polled investment analysts is to buy stock in Acrivon Therapeutics. This Buy consensus rating has held steady for over two years.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Read More
